Value20202021202220232024TTMSelling/general/admin expenses9.8 M10.86 M10.32 M9.73 M9.44 M—Research & development22.76 M28.69 M30.65 M34.47 M24.81 M—Operating income31.5 M35.07 M35.37 M12.99 M14.89 M—Non-Operating Income, Total1.83 M895 K1.78 M3.25 M5.26 M—Interest expense, net of interest capitalized——————Non-Operating Income, excl. Interest Expenses1.83 M895 K1.78 M3.25 M5.26 M—Unusual income/expense——————Pretax income29.7 M34.2 M33.64 M9.78 M9.71 M90.68 MEquity in earnings——————Taxes0058 K8.97 M4.52 M—Non-controlling/minority interest——————After tax other income/expense——————Net income before discontinued operations29.7 M34.2 M33.69 M18.75 M14.23 M90.68 MDiscontinued operations——————Net income29.7 M34.2 M33.69 M18.75 M14.23 M90.68 MDilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders29.7 M34.2 M33.69 M18.75 M14.23 M90.68 MBasic earnings per share (Basic EPS)-0.37-0.41-0.39-0.21-0.16—Diluted earnings per share (Diluted EPS)-0.37-0.41-0.39-0.21-0.161.05Average basic shares outstanding79.59 M84.2 M86.56 M87.63 M89.53 M347.92 MDiluted shares outstanding79.59 M84.2 M86.56 M87.63 M89.53 M347.92 MEBITDA-29.95 M-33.32 M-28.87 M-12.19 M-14.4 M—EBIT-31.5 M-35.07 M-35.37 M-12.99 M-14.89 M—Cost of revenue60 K680 K975 K2 M7.93 M—Other cost of goods sold——————Depreciation & amortization (cash flow)1.54 M1.75 M6.5 M801 K486 K—
Compugen Ltd
Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors.